Connect your AI

Anika Therapeutics ANIK Total Equity

Total Equity at other companies

VericelVCEL

$356.23M+20.6%

Zimmer Biomet HoldingsZBH

$12.67B+2.2%

Pacira BioSciences, Inc.PCRX

$653.89M-18.1%

BioventusBVS

$188.9M+27.5%

Xtant Medical HoldingsXTNT

$48.6M+10.8%

Globus MedicalGMED

$4.73B+15.8%

Other financials

Income statement

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total assets$179.4M-5.9%

Cash flow

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's total equity?: Anika Therapeutics (ANIK) reported total equity of $133.9M in Q1 2026.
How has Anika Therapeutics's total equity changed year-over-year?: Anika Therapeutics's total equity decreased by 9.8% year-over-year, from $148.4M to $133.9M.
What is the long-term trend for Anika Therapeutics's total equity?: Over 5 years (2020 to 2025), Anika Therapeutics's total equity has grown at a -12.0% compound annual growth rate (CAGR), from $272.4M to $143.47M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.